Active ingredient
- atezolizumab
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 00031/0908.
Tecentriq 840 mg and 1,200 mg concentrate for solution for infusion
Package leaflet: Information for the patient
Tecentriq 840 mg concentrate for solution for infusion
Tecentriq 1,200 mg concentrate for solution for infusion
atezolizumab
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
What is in this leaflet
1. What Tecentriq is and what it is used for
2. What you need to know before you are given Tecentriq
3. How Tecentriq is given
4. Possible side effects
5. How to store Tecentriq
6. Contents of the pack and other information
1. What Tecentriq is and what it is used for
What Tecentriq is
Tecentriq is an anti-cancer medicine that contains the active substance atezolizumab.
What Tecentriq is used for
Tecentriq is used in adults to treat:
Patients may get Tecentriq when their cancer has spread to other parts of the body or has come back after previous treatment.
Patients may get Tecentriq when their lung cancer has not spread to other parts of the body and treatment will be given after surgery and chemotherapy. Treatment after surgery is called adjuvant therapy.
Tecentriq may be given in combination with other anticancer medicines. It is important that you also read the package leaflets for the other anticancer medicines you may be receiving. If you have any questions about these medicines, ask your doctor.
How Tecentriq works
Tecentriq works by attaching to a specific protein in your body called programmed death-ligand 1 (PD-L1). This protein suppresses the body’s immune (defence) system, thereby protecting cancer cells from being attacked by the immune cells. By attaching to the protein, Tecentriq helps your immune system to fight your cancer.
2. What you need to know before you are given Tecentriq
You must not be given Tecentriq if:
If you are not sure, talk to your doctor or nurse before you are given Tecentriq.
Warnings and precautions
Talk to your doctor or nurse before you are given Tecentriq if you:
If any of the above applies to you (or you are not sure), talk to your doctor or nurse before you are given Tecentriq.
Tecentriq may cause some side effects that you must tell your doctor about straight away. They may happen weeks or months after your last dose. Tell your doctor straight away if you notice any of the symptoms below:
If you notice any of the symptoms above, tell your doctor straight away.
Do not try to treat yourself with other medicines. Your doctor may:
Tests and checks
Before your treatment, your doctor will check your general health. You will also have blood tests during your treatment.
Children and adolescents
This medicine should not be given to children or adolescents below 18 years of age. This is because the safety and efficacy of Tecentriq have not been established in this age group.
Other medicines and Tecentriq
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
This includes medicines obtained without a prescription, including herbal medicines.
Pregnancy and contraception
Breast-feeding
It is not known if Tecentriq gets into breast milk. Ask your doctor if you should stop breast-feeding or if you should stop treatment with Tecentriq.
Driving and using machines
Tecentriq has minor influence on your ability to drive and use machines. If you feel tired, do not drive or use machines until you feel better.
3. How Tecentriq is given
You will be given Tecentriq by a doctor experienced in cancer treatment in a hospital or clinic.
How much Tecentriq is given
The recommended dose is either:
How Tecentriq is given
Tecentriq is given as a drip into a vein (an intravenous infusion).
Your first infusion will be given over 60 minutes.
How long treatment lasts
Metastatic treatment:
Your doctor will keep giving you Tecentriq until you no longer benefit from it. However, it may be stopped if the side effects become too much of a problem.
Adjuvant treatment:
Your doctor will give you atezolizumab for 1 year of treatment. However, it may be stopped earlier if you no longer benefit from it or the side effects become too much of a problem.
If you miss a dose of Tecentriq
If you miss an appointment, make another one straight away. For the treatment to be fully effective, it is very important to keep having the infusions.
If you stop receiving Tecentriq
Do not stop treatment with Tecentriq unless you have discussed this with your doctor. This is because stopping treatment may stop the effect of the medicine.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor straight away if you notice any of the side effects below or if they get worse. They may happen weeks or months after your last dose. Do not try to treat yourself with other medicines.
Tecentriq used alone
The following side effects have been reported in clinical trials with Tecentriq used alone:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Other side effects that have been reported (frequency not known):
Tecentriq used in combination with anticancer medicines
The following side effects have been reported in clinical trials when Tecentriq is given in combination with anticancer medicines:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
If you notice any of the side effects above or if they get worse, tell your doctor straight away.
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
United Kingdom
or search for MHRA Yellow Card in the Google Play or Apple App Store
5. How to store Tecentriq
Tecentriq will be stored by the healthcare professionals at the hospital or clinic. The storage details are as follows:
Do not throw away any medicines via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help to protect the environment.
6. Contents of the pack and other information
What Tecentriq contains
What Tecentriq looks like and contents of the pack
Tecentriq is a concentrate for solution for infusion. It is a clear, colourless to slightly yellowish liquid.
Tecentriq is available in a pack containing 1 glass vial.
Marketing Authorisation Holder and Manufacturer
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in February 2022
gb-pil-tecentriq-clean-220218-840mg-1200mg-inf
Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
+44 (0)1707 366 000
+44 (0)800 328 1629
+44 (0)800 731 5711
+44 (0)1707 338 297
+44 (0)1707 384555